Best ways to prevent heart disease in breast, prostate, and lung cancer survivors
Official title: Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors
Funded at Icahn School of Medicine at Mount Sinai · NIH-11296887 · Data updated 2026-11-12
It compares prevention options like statins and aspirin to help breast, prostate, and lung cancer survivors lower their risk of heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $698,472 |
| NIH project number | 5R01CA271604-04 |
| Project ID | NIH-11296887 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults who have completed treatment for breast, prostate, or lung cancer and who are worried about or have risk factors for heart disease (for example high cholesterol, high blood pressure, or prior cardiotoxic cancer therapy) would be the primary group this work aims to help.
✕Less likely to help
People currently receiving active cancer therapy, those with very limited life expectancy, or those with no cardiovascular risk factors may be less likely to benefit from the prevention strategies prioritized by this work.
What this research studies
From your perspective as a cancer survivor, researchers will use large patient databases and computer models to estimate heart disease risk after cancer and to see how prevention choices like cholesterol medicines or aspirin might change that risk. The work will account for cancer treatments, other health problems, and genetic risk factors so recommendations fit people with different histories. Models will also consider how cancer recurrence or limited life expectancy might change the long-term benefits of prevention. The goal is to identify which prevention strategies are likely to help specific groups of survivors.
Why it matters
Potential benefit: If successful, this could help doctors pick heart disease prevention approaches that reduce cardiovascular deaths and improve quality of life for cancer survivors.
How similar studies have gone: Statins and aspirin have proven benefits for preventing heart disease in the general population, but applying and tailoring these strategies specifically to cancer survivors is relatively new.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Wisnivesky, Juan P — Icahn School of Medicine at Mount Sinai
- Study coordinator: Wisnivesky, Juan P
Related research
Other NIH-funded projects on the same topics.
-
Aging, DNA Methylation, and Cardio Risk in Breast Cancer Survivors
A study to help breast cancer survivors understand how aging and DNA changes might raise the chance of heart disease.
-
Personalized heart risk prediction for childhood cancer survivors
This project helps predict and lower the chance of heart disease for people who survived cancer as children.
-
Understanding Heart Risks for Childhood Cancer Survivors
This work aims to create better tools to understand and prevent heart problems in people who had cancer as children.
-
Finding the best ways to prevent heart disease in cancer survivors
This study is looking for the best ways to help cancer survivors—especially those who had breast, prostate, or lung cancer—stay heart-healthy by understanding how their cancer treatments and other health factors work together.
-
A program to help cancer survivors increase physical activity and reduce heart disease risk
This study is testing a new program called ActivityChoice that helps cancer survivors find and join physical activity options to lower their chances of heart disease, making it easier for them to choose what works best for them.
-
Understanding how genetic changes in blood cells relate to heart disease in people with HIV
A study will look at how age-related blood cell mutations and large chromosomal changes might contribute to heart disease risk in people living with HIV.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.